Dofetilide: A class III-specific antiarrhythmic agent

Annals of Pharmacotherapy

Volumn 34, Issue 1, 2000, Pages 44-56

  Kalus, James S ^a   Mauro, Vincent F ^a,b  

^a UNIVERSITY OF TOLEDO   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Antiarrhythmic; Dofetilide

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE;

DATA ANALYSIS; DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; REVIEW;

EID: 0033972201     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19185     Document Type: Review

References (64)

1. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991;324:781-8.
2. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-16.
3. Sedgwick ML, Rasmussen HS, Cobbe SM. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol 1992; 69:513-7.
4. Mason JW. Amiodarone. N Engl J Med 1987;316:455-66.
5. Hohnloser SH, Woosley RL. Sotalol. N Engl J Med 1994;331:31-8.
6. Rasmussen HS, Allen MJ, Blackburn KJ, Butrous GS, Dalrymple HW. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992;20(suppl 2):S96-105.
7. Black SC, Chi L, Mu D-X, Lucchesi BR. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent. J Pharmacol Exp Ther 1991;258:416-23.
8. Walker DK, Alabaster CT, Congrave GS, Hargreaves MB, Hyland R, Jones BC, et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. Drug Metab Dispos 1996;24: 447-55.
9. Vaughan Williams EM. Classifying antiarrhythmic actions: by fact or speculation. J Clin Pharmacol 1992;32:964-77.
10. Gwilt M, Arrowsmith JE, Blackburn KJ, Burges RA, Cross PE, Dalrymple HW, et al. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991;256:318-24.
11. k blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990;16:401-10.
12. Gwilt M, Solca AM, Burges RA, Blackburn KJ, Higgins AJ. Antifibrillatory action and haemodynamic properties of UK-68,798, a new class in antiarrhythmic agent, in anaesthetised dogs (abstract). J Mol Cell Cardiol 1989;21(suppl 2):S11.
13. Gwilt M, King RC, Milne AA, Solca AM. Dofetilide, a new class III anitarrhythmic agent, reduces pacing induced heterogeneity of repolarisation in vivo. Cardiovasc Res 1992;26:1102-8
14. Yang T, Tande PM, Lathrop DA, Refsum H. Class III antiarrhythmic action by potassium channel blockade: dofetilide attenuates hypoxia induced electromechanical changes. Cardiovasc Res 1992;26:1109-15.
15. Yang T, Tande PM, Refsum H. Negative chronotropic effect of a novel class III antiarrhythmic drug, UK-68,798, devoid of β-blocking action on isolated guinea-pig atria. Br J Pharmacol 1991;103:1417-20.
16. + current by dofetilide. Circ Res 1993;72:75-83.
17. max. Br J Pharmacol 1991;103:1568-72.
18. Gwilt M, Milne AA, Solca AM, King RC. UK-68,798, a potent and selective class III antiarrhythmic agent, reduces dispersion of repolarisation in canine hearts in situ induced by rapid pacing (abstract). Br J Pharmacol 1990;99:15P.
19. Zuanetti G, Corr PB. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping. J Pharmacol Exp Ther 1991;256:325-34.
20. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990;16:276-85.
21. Dalrymple HW, Butler P, Sutton MR, Dodd MG. Effects of UK-68,798, a novel class III antiarrhythmic agent, in conscious dogs (abstract). J Mol Cell Cardiol 1989;21(suppl 2):S10.
22. Mortensen E, Yang T, Refsum H. Class III antiarrhythmic action and inotropy: effects of dofetilide in acute ischemic heart failure in dogs. J Cardiovasc Pharmacol 1992;19:216-21.
23. Howard PA. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutler. Ann Pharmacother 1999;33:38-47.
24. Cropp JS, Antal EG, Talbert RL. Ibutilide: a new class III antiarrhythmic agent. Pharmacotherapy 1997;17:1-9.
25. Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 1992;70:1432-7.
26. Kobayashi Y, Atarashi H, Ino T, Kuruma A, Nomura A, Saitoh H, et al. Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 1997;30: 367-73.
27. Gemmill JD, Howie CA, Meredith PA, Kelman AW, Rasmussen HS, Hillis WS, et al. A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers. Br J Clin Pharmacol 1991; 32:429-32.
28. Tham TCK, MacLennan BA, Burke MT, Harron DWG. Pharmacodynamics and pharmacokinetics of the class III agent dofetilide (UK-68,798) in humans. J Cardiovasc Pharmacol 1993;21:507-12.
29. Sedgwick ML, Lip G, Rae AP, Cobbe SM. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol 1995;49:159-66.
30. Bashir Y, Thomsen P-EB, Kingma JH, Moller M, Wong C, Cobbe SM, et al. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol 1995;76: 1040-4.
31. Bailey WM, Nademanee K, Edwards J, Di Pasquale J, Adair O, Friedrich T. Electrophysiologic and hemodynamic effects of dofetilide in patients with severe left ventricular dysfunction (abstract). Circulation 1992;86(suppl):I-265.
32. Yuan S, Wohlfart B, Rasmussen HS, Olsson S, Blomstrom-Lundqvist C. Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia: a study using simultaneous monophasic action potential recordings from two sites in the right ventricle. Eur Heart J 1994; 15:514-22.
33. Demolis J-L, Frunck-Brentano C, Ropers J, Ghadanfar M, Nichols DJ, Jaillon P. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996;94: 1592-9.
34. Crijns HJGM, Kingma JH, Gosselink ATM, Lie KI. Comparison in the same patient of aberrant conduction and bundle branch reentry after dofetilide, a new selective class III antiarrhythmic agent. PACE 1993;16: 1006-16.
35. Crijns HJGM, Kingma JH, Gosselink ATM, Dalrymple HW, De Langen CDJ, Lie KI. Sequential bilateral bundle branch block during dofetilide, a new class in antiarrhythmic agent, in a patient with atrial fibrillation. J Cardiovasc Electrophysiol 1993;4:459-66.
36. Gremillion ST, Echt DS, Smith NA, Winkle RA, Friedrich T, Kopp D, et al. Beneficial effects of intravenous dofetilide in patients undergoing ventricular defibrillation testing (abstract). Circulation 1992;86(suppl 1): 1-264.
37. Smith DA, Rasmussen HS, Stopher DA, Walker DK. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog, and man. Xenobiotica 1992;22:709-19.
38. Sedgwick M, Rasmussen HS, Walker D, Cobbe SM. Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug. Br J Clin Pharmacol 1991;31:515-9.
39. Le Coz F, Funck-Brentano C, Morell T, Ghadanfar MM, Jaillon P. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin Pharmacol Ther 1995;57:533-42.
40. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 1997;29:385-90.
41. The DIAMOND study group. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Clin Cardiol 1997;20:704-10.
42. Echt DS, Lee JT, Murray KT, Vorperian V, Borganelli SM, Crawford DM, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol 1995;6:687-99.
43. Rasmussen HS, Kleinetmans D, Walker D, Rapeport WG. A double-blind, placebo controlled parallel group study of the effect of UK-68,798, a novel class III antiarrhythmic agent, on the pharmacokinetics and pharmacodynamics of digoxin (abstract). Eur Heart J 1990;11(suppl):57.
44. Vincent J, Gardner M, Scavone J, Ashton H, Willavize S, Friedman HL. The effect of dofetilide on the steady-state PK and cardiac effects of phenytoin in healthy subjects (abstract). Clin Pharmacol Ther 1997;61: 233
45. Gardner MJ, Ashton HM, Willavize SA, Vincent J. The effects of orally administered theophylline on the pharmacokinetics and pharmacodynamics of dofetilide (abstract). Clin Pharmacol Ther 1996;59:182.
46. Vincent J, Gardner MJ, Barns B, Willavize SA. Concurrent administration of omeprazole and antacid does not alter the pharmacokinetics and pharmacodynamics of dofetilide in healthy subjects (abstract). Clin Pharmacol Ther 1996;59:182.
47. Suttorp MJ, Polak PE, van't Hof A, Rasmussen HS, Dunselman PH, Kingma JH. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol 1992;69:417-9.
48. Norgaard BL, Wachtell K, Christensen PD, Madsen B, Johansen JB, Christiansen EH, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter a multicenter, randomized, double-blind, placebo-controlled trial. Am Heart J 1999;137:1062-9.
49. Niazi IK, Sweidan R, Lanzarotti CJ, Kiemen J. Intravenous dofetilide for termination of paroxysmal supraventricular tachycardia (abstract). J Am Coll Cardiol 1998;31(suppl A):473A.
50. Krahn A, Klein G. Lee J, Yee R. Efficacy and safety of intravenous dofetilide in acute conversion of supraventricular arrhythmias in Wolff Parkinson White syndrome (abstract). J Am Coll Cardiol 1998;31(suppl A):473A.
51. Frost L, Mortensen PE, Tingleff J, Platou ES, Christiansen EH, Christiansen N, et al. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Int J Cardiol 1997;58:135-40.
52. Crijns HJGM, Van Gelder IC, Kingma JH, Dunselman PHJM, Gosselink ATM, Lie KI. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. Eur Heart J 1994;15:1403-8.
53. Bianconi L, Dinelli M, Pappalardo A, Richiardi E, Castro A, Alboni P, et al. Comparison of intravenously-administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multi-center, randomized, double-blind, placebo-controlled study (abstract). Circulation 1995;92(suppl I):I-774.
54. Green MS, Dorian P, Roy D, Sterns L, Connolly SJ, Ellenbogen KA, et al. A randomized, double-blind, placebo-controlled comparison of intravenous dofetilide and procainamide in the acute conversion of atrial fibrillation/flutter (abstract). Circulation 1997;96(suppl I):I-453.
55. Greenbaum RA, Campbell TJ, Channer KS, Dalrymple HW, Kingma JH, Santini M, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) Study (abstract). Circulation 1998;98(suppl I):I-633.
56. Ferguson JJ. Meeting highlights. Highlights of the 71st Scientific Sessions of the American Heart Association. Circulation 1999;99:2486-91.
57. Connelly DT, Thomsen PEB, Camm AJ, Morgan JM, Jordaens L, Butrous GS, et al. Efficacy and safety of dofetilide, a novel class III antiarrhythmic agent, in atrioventricular nodal reentrant tachycardia (abstract). Eur Heart J 1992;13(suppl):304.
58. Wong CKY, Heald S, Thomsen PEB, Jordaens L, Connelly DT, Rasmussen HS, et al. Electrophysiology, safety, and efficacy of dofetilide in patients with atrioventricular reentrant tachycardia (AVRT): a dose range study (abstract). Eur Heart J 1992;13(suppl):211.
59. Singh SN, Berk MR, Yellen LG, Zoble RG, Haley JA, Abrahamson D, et al. Efficacy and safety of oral dofetilide in maintaining normal sinus rhythm in patients with atrial fibrillation/flutter. A multicenter study (abstract). Circulation 1997;96(suppl):I-383.
60. Wnuk-Wojnar AM, Tendera M, Kulakowski P, Graff O. Efficacy and safety of dofetilide in the prevention of symptomatic attacks of paroxysmal supraventricular tachycardia (abstract). J Am Coll Cardiol 1999;33 (suppl A):156A.
61. Brachmann J, Haverkamp W, Johns J, Zehender M, Kingma HG, Wiecha J, et al. The efficacy and safety of oral dofetilide in patients with sustained ventricular tachycardia (abstract). Circulation 1992;86(suppl): I-265.
62. Kober L, The DIAMOND study group. A clinical trial of dofetilide in patients with acute myocardial infarction and left ventricular dysfunction: the DIAMOND MI study (abstract). Eur Heart J 1998;19(suppl):90.
63. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857-65.
64. Pedersen OD, The DIAMOND study group. Dofetilide in the treatment of atrial fibrillation in patients with impaired left ventricular function: atrial fibrillation in the DIAMOND study (abstract). Circulation 1998;98 (suppl I):I-632.